Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (DE:EX9)
BERLIN:EX9
Exelixis (EX9) Stock Price & Analysis
0 Followers
EX9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€16.34 - €21.78
Previous Close€20.69
Volume0.00
Average Volume (3M)N/A
Market Cap
€6.22B
Enterprise Value€5.47B
Total Cash (Recent Filing)$995.30M
Total Debt (Recent Filing)$189.94M
Price to Earnings (P/E)N/A
Beta-0.03
Next Earnings
Apr 30, 2024EPS Estimate
€0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding303,194,259
10 Day Avg. Volume16
30 Day Avg. VolumeN/A
Standard Deviation0.23
R-Squared0.04
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)3.10
Price to Sales (P/S)10.15
Price to Cash Flow (P/CF)161.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.99
Enterprise Value/Gross Profit3.11
Enterprise Value/Ebitda19.30
Forecast
1Y Price Target
€25.08Price Target Upside21.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Exelixis News
PremiumCompany Announcements
Jacqueline Wright to Exit Exelixis Board in 2024
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company's robust financial position is underscored by a substantial cash reserve and a strategic share repurchase program, indicating a commitment to delivering shareholder value.
Intellectual Property ResolutionsResolution of the intellectual property issue could significantly enhance the stock valuation and potentially position the company as an attractive merger and acquisition target.
Product Sales PerformanceCabozantinib's sales are meeting market expectations, reflecting strong demand for the product, which supports the company's growth trajectory.
Bears Say
Drug Approval And Market CompetitionMSN has not received tentative approval from the FDA for its generic drug.
Financial Performance And Growth OutlookRevenue guidance lower than consensus, attributed to Cabometyx market saturation.
Legal And Regulatory ChallengesKOL's reduced likelihood of MSN winning the case to 70%.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.81% Other Institutional Investors
98.19% Public Companies and
Individual Investors
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was €16.34 and its highest was €21.78 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Apr 30, 2024 which is in 5 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Feb 06, 2024. The company reported €0.253 earnings per share for the quarter, beating the consensus estimate of €0.216 by €0.038.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is €0.21.
How many shares outstanding does Exelixis have?
Currently, no data Available
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of €0.253 in its last earnings report, beating expectations of €0.216. Following the earnings report the stock price went up 1.546%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 639M.
---
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€25.08 (21.21% Upside)
€25.08 (21.21% Upside)
Blogger Sentiment
Bullish
DE:EX9 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.53%
12-Months-Change
Fundamentals
Return on Equity
8.74%
Trailing 12-Months
Asset Growth
-2.44%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EX9 Company Deck
---
EX9 Earnings Call
Q4 2024
0:00 / 0:00
---
EX9 Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
EX9 Stock 12 Months Forecast
Average Price Target
€25.08
▲(21.21% Upside)
Technical Analysis
Best Analysts Covering EX9
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+103.43%
reiterated a buy rating 7 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +103.43% per trade.
---